Desentum raises EUR 28 million for allergy vaccines
Finnish clinical-stage biotech Desentum has completed an oversubscribed equity funding round, raising EUR 28 million to advance its allergy vaccine initiatives. The funding will facilitate the progression of their lead…
Nordic Life Science Read story →